U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540442) titled 'A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis' on April 13.
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Study Start Date: April 17
Study Type: INTERVENTIONAL
Condition:
Dermatitis, Atopic
Intervention:
DRUG: MG-K10 Injection (Humanized Monoclonal Antibody)
loading dose (SC) at Week 0, followed by a single dose Q2W through Week 52
DRUG: Placebo for MG-K10
Initial loading dose (SC), then single dose Q2W through Week 52
Re...